Content and Criterion Validity of the Preliminary Core Dataset for Clinical Trials in Fibromyalgia Syndrome

REFERENCES

1. 1.↵
   1. Wolfe F,
   2. Ross K,
   3. Anderson J,
   4. Russell IJ,
   5. Hebert L

   . The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19–28.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Wolfe F,
   2. Smythe HA,
   3. Yunus MB,
   4. et al.

   The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the multicenter criteria committee. Arthritis Rheum 1990;33:160–72.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Boonen A,
   2. van den Heuvel R,
   3. van Tubergen A,
   4. et al.

   Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis 2005;64:396–402.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Hughes G,
   2. Martinez C,
   3. Myon E

   . The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: An observational study based on clinical practice. Arthritis Rheum 2006;54:177–83.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Tugwell P,
   2. Boers M,
   3. Brooks P,
   4. Simons L,
   5. Strand V,
   6. Idzerda L

   . OMERACT: An international initiative to improve outcome measurement in rheumatology. Trials 2007;8:38–43.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Arnold LM,
   2. Crofford LJ,
   3. Mease PJ,
   4. et al.

   Patient perspectives on the impact of fibromyalgia. Patient Edu Couns 2008;73:114–20.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Mease PJ,
   2. Arnold LM,
   3. Crofford LJ,
   4. et al.

   Identifying the clinical domains of fibromyalgia: Contributions from clinical and patients delphi exercises. Arthritis Care Res 2008;59:952–60.

   OpenUrlCrossRef
8. 8.↵
   1. Mease P,
   2. Arnold LM,
   3. Bennett R,
   4. et al.

   Fibromyalgia syndrome. J Rheumatol 2007;34:1415–25.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Mease PJ,
   2. Clauw DJ,
   3. Arnold LM,
   4. et al.

   Fibromyalgia syndrome. J Rheumatol 2005;32:2270–7.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Carville SF,
    2. Choy EH

    . Systematic review of discriminating power of outcome measures used in clinical trials of fibromyalgia. J Rheumatol 2008;35:2094–105.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Beck AT,
    2. Ward CH,
    3. Mendelson M,
    4. Mock J,
    5. Erbaugh J

    . An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–71.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Stewart AL,
    2. Hays RD,
    3. Ware JE, Jr

    . The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988;26:724–35.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Stewart AL,
    2. Ware JE,
    3. Brook RH,
    4. Davies AR

    . Conceptualization and measurement of health for adults in the Health Insurance Study. Vol II Physical health in terms of functioning. Santa Monica: RAND Corporation; 1978:236–359.
14. 14.↵
    1. Burckhardt CS,
    2. Clark SR,
    3. Bennett RM

    . The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991;18:728–33.

    OpenUrlPubMed
15. 15.↵
    1. Moldofsky H,
    2. Scarisbrick P,
    3. England R,
    4. Smythe HA

    . Musculoskeletal symptoms and non-REM sleep disturbance in patients with “fibrositis syndrome” and healthy subjects. Psychosom Med 1975;37:341–5.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Mease P,
    2. Arnold LM,
    3. Choy EH,
    4. et al.

    Fibromyalgia syndrome. J Rheumatol 2009;36:2318–29.

    OpenUrlAbstract/FREE Full Text